

Rosella Ciurleo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7520474/publications.pdf>

Version: 2024-02-01

39
papers

1,202
citations

471509

17
h-index

377865

34
g-index

40
all docs

40
docs citations

40
times ranked

1972
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of MAO-B Inhibitors on Neurometabolic Profile of Patients Affected by Parkinson Disease: A Proton Magnetic Resonance Spectroscopy Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1931.	2.4	1
2	Anxiety, depression, and quality of life in Parkinson's disease: the implications of multidisciplinary treatment. <i>Neural Regeneration Research</i> , 2021, 16, 587.	3.0	13
3	The impact of the SARS-COV2 infection on the disorder of consciousness rehabilitation unit. <i>PLoS ONE</i> , 2021, 16, e0253958.	2.5	1
4	Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	19
5	Striatal topographical organization: Bridging the gap between molecules, connectivity and behavior. <i>European Journal of Histochemistry</i> , 2021, 65, .	1.5	7
6	Emerging Neurological and Psychobiological Aspects of COVID-19 Infection. <i>Brain Sciences</i> , 2020, 10, 852.	2.3	33
7	Parosmia and Neurological Disorders: A Neglected Association. <i>Frontiers in Neurology</i> , 2020, 11, 543275.	2.4	16
8	Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. <i>Autoimmunity Reviews</i> , 2020, 19, 102571.	5.8	92
9	Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). <i>International Journal of Molecular Medicine</i> , 2020, 46, 903-912.	4.0	73
10	Olfactory event-related potentials in a functionally anosmic patient with arrested hydrocephalus. <i>Journal of International Medical Research</i> , 2019, 47, 1353-1358.	1.0	1
11	Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis. <i>Medicine (United States)</i> , 2019, 98, e15185.	1.0	6
12	Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson's disease and their caregivers. <i>Journal of Neurology</i> , 2018, 265, 2005-2014.	3.6	26
13	Olfactory dysfunction as a prognostic marker for disability progression in Multiple Sclerosis: An olfactory event related potential study. <i>PLoS ONE</i> , 2018, 13, e0196006.	2.5	13
14	Role of diffusion tensor imaging in the diagnosis and management of post-traumatic anosmia. <i>Brain Injury</i> , 2017, 31, 1964-1968.	1.2	7
15	The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis. <i>Medicine (United States)</i> 10.784314 rgBTg/Overlook	1.0	
16	Automatic Algorithm for Segmentation of Atherosclerotic Carotid Plaque. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 411-416.	1.6	10
17	Functional Evaluation of Awareness in Vegetative and Minimally Conscious State. <i>Open Neuroimaging Journal</i> , 2017, 11, 17-25.	0.2	17
18	Effect of the antiepileptic therapy on olfactory disorders associated with mesial temporal sclerosis. <i>Neurocase</i> , 2016, 22, 357-361.	0.6	10

#	ARTICLE	IF	CITATIONS
19	Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study. <i>Neuroscience Letters</i> , 2015, 599, 55-60.	2.1	5
20	Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. <i>Journal of Neural Transmission</i> , 2015, 122, 799-808.	2.8	7
21	Detection of Olfactory Dysfunction Using Olfactory Event Related Potentials in Young Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e103151.	2.5	31
22	Post-traumatic olfactory loss: Psychophysical, electrophysiological and neuroradiological findings in three single case studies. <i>Brain Injury</i> , 2014, 28, 1776-1780.	1.2	7
23	Magnetic Resonance Spectroscopy: An In Vivo Molecular Imaging Biomarker for Parkinson's Disease?. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	38
24	Cortical reorganization in multiple sclerosis after intrathecal baclofen therapy. <i>Neurocase</i> , 2014, 20, 225-229.	0.6	3
25	Role of statins in the treatment of multiple sclerosis. <i>Pharmacological Research</i> , 2014, 87, 133-143.	7.1	41
26	Pharmacotherapy for Disorders of Consciousness: Are "Awakening" Drugs Really a Possibility?. <i>Drugs</i> , 2013, 73, 1849-1862.	10.9	46
27	Persistent anosmia in a traumatic brain injury patient: Role of orbitofrontal cortex. <i>Brain Injury</i> , 2013, 27, 1715-1718.	1.2	15
28	Evaluation of olfactory dysfunction in neurodegenerative diseases. <i>Journal of the Neurological Sciences</i> , 2012, 323, 16-24.	0.6	167
29	Magnetic resonance imaging markers for early diagnosis of Parkinson's disease. <i>Neural Regeneration Research</i> , 2012, 7, 611-9.	3.0	13
30	¹ H-MR Spectroscopy in Traumatic Brain Injury. <i>Neurocritical Care</i> , 2011, 14, 127-133.	2.4	55
31	Neurogenic Ejaculatory Disorders: Focus on Current and Future Treatments. <i>Recent Patents on CNS Drug Discovery</i> , 2011, 6, 205-221.	0.9	15
32	Identification of new non-carboxylic acid containing inhibitors of aldose reductase. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4049-4055.	3.0	33
33	Structure-Based Optimization of Benzoic Acids as Inhibitors of Protein Tyrosine Phosphatase 1B and Low Molecular Weight Protein Tyrosine Phosphatase. <i>ChemMedChem</i> , 2009, 4, 957-962.	3.2	32
34	5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1928-1937.	3.0	79
35	2/4-Substituted-9-fluorenones and their O-glucosides as potential immunomodulators and anti-herpes simplex virus-2 agents. Part 5. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 2656-2664.	5.5	14
36	Synthesis, induced-fit docking investigations, and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 5840-5852.	3.0	58

#	ARTICLE	IF	CITATIONS
37	5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 5137-5149.	3.0	104
38	Synthesis and in vitro evaluation of 5-arylidene-3-hydroxyalkyl-2-phenylimino-4-thiazolidinones with antidegenerative activity on human chondrocyte cultures. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 7618-7625.	3.0	32
39	Evaluation of in vitro aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3886-3893.	2.2	54